Tripta Bansal

Emerging Significance of Flavonoids as P-Glycoprotein Inhibitors in Cancer Chemotherapy

Tripta Bansal, Manu Jaggi, Roop Khar et al. · Journal of Pharmacy & Pharmaceutical Sciences · 2009 · 236 citations · Full text

Effect of P-glycoprotein inhibitor, verapamil, on oral bioavailability and pharmacokinetics of irinotecan in rats

Tripta Bansal, Gautam Mishra, Manu Jaggi et al. · European Journal of Pharmaceutical Sciences · 2008 · 138 citations

Oral Bioavailability, Pharmacological Study, P-glycoprotein Inhibitor +4

Pre-clinical evidence for altered absorption and biliary excretion of irinotecan (CPT-11) in combination with quercetin: Possible contribution of P-glycoprotein

Tripta Bansal, Anshumali Awasthi, Manu Jaggi et al. · Life Sciences · 2008 · 68 citations

Urology, Pre-clinical Evidence, Gastrointestinal Pharmacology +8

Development and validation of reversed phase liquid chromatographic method utilizing ultraviolet detection for quantification of irinotecan (CPT-11) and its active metabolite, SN-38, in rat plasma and bile samples: Application to pharmacokinetic studies

Tripta Bansal, Anshumali Awasthi, Manu Jaggi et al. · Talanta · 2008 · 52 citations

Pharmacokinetic Studies, Pharmaceutical Science, Biochemistry +10

Concurrent determination of topotecan and model permeability markers (atenolol, antipyrine, propranolol and furosemide) by reversed phase liquid chromatography: Utility in Caco-2 intestinal absorption studies

Tripta Bansal, Manoj Kumar Singh, Gautam Mishra et al. · Journal of Chromatography B · 2007 · 47 citations

Concurrent Determination, Medicine, Physiology +10